BUZZ-scPharmaceuticals rises after MannKind's buyout deal

Reuters08-25
BUZZ-scPharmaceuticals rises after MannKind's buyout deal

** Shares of drugmaker scPharmaceuticals SCPH.O rise 13.2% to $5.48 premarket

** Biotech firm MannKind Corp's MNKD.O to buy scPharmaceuticals in a deal valued up to $360 million, companies say

** MNKD's shares fall 2% to $4.03 premarket

** Under the deal, MNKD will pay $5.35 per share upfront in cash, plus offer a non-tradable CVR worth up to $1 per share if certain regulatory and sales milestones are met

** The deal will allow MannKind to expand its portfolio beyond orphan lung diseases

** SCPH brings Furoscix, an FDA-approved on-body infuser to treat adults with chronic heart failure and kidney disease with over $10 billion market opportunity in U.S., according to the companies

** The transaction is expected to close in Q4

** Up to last close, MNKD down 36.1%, while SCPH up 37% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment